Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087372 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Yaakub Azhany und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Wilayah Persekutuan, Malaysia. Hauptthemen laut MEDLINE: Trabeculectomy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universiti Sains Malaysia.
Abstract (Originalsprache)
Post-surgical scarring is a known cause of trabeculectomy failure. The aim of this study was to investigate the effectiveness of ranibizumab as an adjuvant anti-scarring agent in experimental trabeculectomy. Forty New Zealand white rabbits were randomised into four eye treatment groups: groups A (control), B (ranibizumab 0.5 mg/mL), C (mitomycin C [MMC] 0.4 mg/mL), and D (ranibizumab 0.5 mg/mL and MMC 0.4 mg/mL). Modified trabeculectomy was performed. Clinical parameters were assessed on post-operative days 1, 2, 3, 7, 14, and 21. Twenty rabbits were euthanised on day 7, and the other twenty were euthanised on day 21. Eye tissue samples were obtained from the rabbits and stained with haematoxylin and eosin (H&E). All treatment groups showed a significant difference in IOP reduction compared with group A (p < 0.05). Groups C and D showed a significant difference in bleb status on days 7 (p = 0.001) and 21 (p = 0.002) relative to group A. H&E staining showed significantly low fibrotic activity (p < 0.001) in group C on both days and inflammatory cell grade in group B on day 7 (p < 0.001). The grade for new vessel formation was significantly low in groups B and D on day 7 (p < 0.001) and in group D on day 21 (p = 0.007). Ranibizumab plays a role in reducing scarring, and a single application of the ranibizumab–MMC combination showed a moderate wound-modulating effect in the early post-operative phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Wilayah Persekutuan, Malaysia.
- Department of Ophthalmology & Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.
- Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.
- Department of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.
ORCID-Profile: Yaakub Azhany, Wan Faiziah Wan Abdul Rahman, Wan Nazirah Wan Yusuf, Jemaima Che Hamzah
Förderung
- Universiti Sains Malaysia
Zitieren
APA
Azhany, Y., Rahman, W. F. W. A., Jaafar, H., Low, J. H., Yusuf, W. N. W., Liza-Sharmini, A. T., & Che Hamzah, J. (2023). Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087372
Vancouver
Azhany Y, Rahman WFWA, Jaafar H, Low JH, Yusuf WNW, Liza-Sharmini AT, et al. Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087372
BibTeX
@article{Azhany2023,
author = {Azhany, Yaakub and Rahman, Wan Faiziah Wan Abdul and Jaafar, Hasnan and Low, Jen Hou and Yusuf, Wan Nazirah Wan and Liza-Sharmini, Ahmad-Tajudin and Che Hamzah, Jemaima},
title = {Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087372}
}
EUVIMED